Biotech Catalyst Trading Strategy
Catalyst-driven biotech can produce 50-300% single-day moves. Here's the framework that pros use to capture asymmetric returns without blowing up.
Start free with Clinical Investor âCatalyst-driven biotech trading is one of the few areas where an individual investor can have an edge. Public information about trial design, sponsor history, and indication base rates is often mispriced because most retail investors don't do the work. Here's the playbook.
Categories of catalysts and their typical move sizes
| Catalyst | Typical move | Time horizon |
|---|---|---|
| Phase 2 data readout | −40% to +100% | Single day |
| Phase 3 data readout | −60% to +200% | Single day |
| FDA AdCom (Advisory Committee) | −20% to +30% | Days |
| PDUFA decision | −50% to +50% | Single day |
| FDA filing acceptance | +5% to +20% | Days |
| Partnership / licensing announcement | +10% to +100% | Days |
| SPA agreement (Special Protocol Assessment) | +5% to +25% | Days |
Position sizing for binary outcomes
Treat each catalyst trade as a binary bet:
- Estimate probability of success (POS) using base rates by indication + your read of the trial
- Estimate upside if positive, downside if negative
- Calculate expected value (EV) = POS × Upside − (1−POS) × Downside
- Only trade EV-positive setups
- Position size such that worst case (catalyst miss) doesn't exceed 1-2% of portfolio
Example: $1B mcap biotech with Phase 3 readout. POS = 60% (you think the trial design is strong). Upside if positive: +80%. Downside if negative: −60%. EV = (0.6 × 80) − (0.4 × 60) = +24%. Position-sized at 2% of portfolio; risk = 2% × 60% = 1.2% of portfolio at risk.
Options strategies for catalyst events
- Long puts/calls: Simplest expression of binary view. Cheaper than buying stock, capped downside. IV is very high around catalysts so premium is expensive.
- Long straddles: Buy ATM call + ATM put. Bets on big move in either direction. Wins on outcome surprises. Loses if move is smaller than priced in (which is often).
- Short straddles: Sell call + put. Wins if the move is smaller than IV implies. High-risk; one big miss can wipe out months of gains.
- Risk reversals: Sell put, buy call (or vice versa). Synthetic long/short with leverage; common professional setup.
Common mistakes
- Holding through binary catalysts at full position size when you intended a "trade"
- Ignoring base rates â Phase 3 oncology trials have ~50% success; Phase 3 CNS trials have ~20%
- Buying calls right before catalyst when IV has already pumped 200% â you're paying for the move that's expected, not the surprise
- Adding to losing positions on the assumption that "the data will come"
Get the catalyst calendar + Trial Translator
Free tier: weekly catalyst briefing, basic company profiles. Premium ($19/mo): real-time alerts, unlimited Trial Translator, deep dives.
Start free âFrequently Asked Questions
- What is a base rate for biotech trial success?
- By phase: Phase 1 â Phase 2 ~63% pass rate. Phase 2 â Phase 3 ~31%. Phase 3 â approval ~58%. By indication, oncology is the most studied (~50% Phase 3 success); CNS is the lowest (~20%); rare disease often higher.
- Should I use options for catalyst trades?
- Options are powerful but expensive around catalysts (IV is pumped). They make sense if you have strong directional conviction OR you want defined-risk exposure. They're bad if you're paying premium for the consensus expectation.
- How do I know if a catalyst is "priced in"?
- Compare current implied volatility to historical (the IV "pump"). If a stock has IV of 250% vs. baseline 80%, the market is pricing in a ±15% move. If you think the move will be larger, IV is undervalued; if smaller, IV is overvalued.
- Can I trade catalyst events full-time?
- A few people do, but it requires extreme discipline on position sizing and the ability to walk away from EV-negative setups. Most full-time traders also have a portfolio of more boring strategies that smooth out the variance.
Related guides
Educational only. Not investment advice. Biotech investing carries substantial risk; consult a licensed advisor.